کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
494429 862792 2016 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment
ترجمه فارسی عنوان
علاقه ارائه دهندگان مراقبت های اولیه در استفاده از یک آزمون ژنتیکی برای هدایت درمان اختلال مصرف الکل
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی روانپزشکی بیولوژیکی
چکیده انگلیسی


• Efforts to identify genetic moderators of response to pharmacotherapy for AUD have generated interest in clinical translation, but no study has assessed provider interest.
• Findings of this multi-site qualitative study suggest that primary care providers were interested in using a genetic test to guide provision of AUD pharmacotherapy, due to its potential to hone treatment choices as well as to influence patient motivation and adherence to treatment.
• Because treatment of AUD with pharmacotherapy is effective but rarely received by patients with AUD, provider interest in pharmacogenetics testing may be one method of facilitating increased provision of AUD pharmacotherapy.

BackgroundEfforts to identify genetic moderators of pharmacotherapy response have generated interest in clinical applications of pharmacogenetic tests in alcohol use disorder (AUD) treatment. To date, no research on providers' interest in using pharmacogenetic tests in the context of AUD treatment has been reported. We conducted qualitative interviews with primary care providers from 5 clinics in the Veterans Health Administration (VA) to assess their interest in using a hypothetical genetic test to inform treatment of AUD with pharmacotherapy.MethodsKey contacts were used to recruit 24 providers from 5 primary care clinics associated with a single large VA medical facility. Participants completed 30-minute in-person semi-structured interviews focused on barriers and facilitators to provision of pharmacotherapy for AUD. Interviews included a hypothetical scenario regarding the availability of a genetic test to inform AUD pharmacotherapy provision and/or selection. Provider responses to the hypothetical scenario were recorded, transcribed and analyzed qualitatively using inductive content analysis. Data were independently coded by three investigators, and themes were identified via consensus.ResultsParticipants were generally interested in a genetic test to aid in AUD treatment planning. Five common themes were identified, including: perceived benefits of a pharmacogenetic test (e.g., aiding with therapeutic choice, positively impacting patient motivation for and engagement with AUD treatment), perceived drawbacks (e.g., limiting potential benefits of pharmacotherapy by reducing the target population for its receipt, adverse impacts of “negative” results), caveats to clinical utility (e.g., utility would depend on prognostic accuracy and/or medication characteristics), uncertainty as to whether such a test would impact clinical decision-making, and pragmatic barriers to use (costs and other resources, such as laboratory facilities).ConclusionsPrimary care providers in this study generally believed a genetic test to aid in AUD treatment planning would be useful, due to its potential to hone treatment choice as well as to influence patient motivation and adherence to treatment. However, providers acknowledged that a test's utility would depend on the strength of its prognostic characteristics, its other benefits relative to standard care, and lack of pragmatic barriers.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Substance Abuse Treatment - Volume 70, November 2016, Pages 14–20
نویسندگان
, , , ,